Search

everythinglearnresearchcommunity

for

Search:↓

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

The conversation is about the availability of Breezula, a hair loss treatment, with speculation it might be released in 2022 or potentially never, as it's more effective than finasteride. No specific treatments were confirmed.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The conversation discusses Kevin's accurate information on hair loss treatments and highlights Dr. Bloxham's ongoing work with Verteporfin on FUT scars, suggesting people follow Dr. Bloxham's YouTube for updates. It also thanks Haicafe and Melvin from the hair restoration network forum for their contributions.

Pumpkin seed oil is a weak natural DHT inhibitor and not effective for significant hair loss. Effective treatments include finasteride, minoxidil, and other medications.

The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.

The user experienced significant hair regrowth using a combination of minoxidil, finasteride, various serums, and micro-needling, leading to increased confidence and consideration of a hair transplant. Despite initial baldness due to past health issues, the user is pleased with the progress and continues to use treatments like Pilgrim, Md Hair, Bodywise Roller, and Bouf serums.

Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.

Men with hair loss might have lichen planopilaris (LPP), which can mimic androgenetic alopecia, leading to misdiagnosis and ineffective treatment with finasteride or dutasteride. Proper diagnosis, including biopsies, is crucial to distinguish between androgenetic alopecia and conditions like LPP.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

A user experienced a "watery belly" and cellulite after starting finasteride, despite maintaining a disciplined fitness routine. Others suggest checking hormone levels, as changes in DHT and estrogen could affect fat metabolism, but age might also be a factor.

A 20-year-old is concerned about hairline changes and wonders if it's maturing or male pattern baldness (MPB). Suggestions include consulting a specialist and considering treatments like finasteride or minoxidil.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

User noticed beard and sideburn hair loss, and thinning eyebrows, diagnosed with alopecia barbae and male pattern baldness, and prescribed Desonide cream. User seeks feedback on Desonide cream.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation discusses experiences with Procapil for hair loss treatment. A user inquires about purchasing Procapil and provides a link to a product website.

An 18.5-year-old experiencing rapid hair loss is being treated with saw palmetto, vitamins, and red light therapy, but these seem ineffective. The consideration of finasteride is discussed, weighing its potential side effects against the emotional impact of early hair loss.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The conversation discusses hair loss caused by Trenbolone use, with suggestions to stop using it and consider treatments like Minoxidil, Dutasteride, and RU58841. It highlights that Minoxidil may temporarily regrow hair, but stopping Trenbolone is crucial to prevent further hair loss.